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Abstract 
 
Aims 
Treatment decision-making and planning in patients with oesophageal cancer (OC) 
are guided by radiological measurement of length of disease (LoD).  This study 
aimed to investigate differences in PET and EUS LoD.  Their prognostic significance 
was also assessed. 
 
Materials & Methods 
LoD was measured from PET and EUS staging investigations by one observer for 
each modality.  Bland-Altman analysis and Wilcoxon signed rank tests assessed 
agreement and differences in measurements.  In terms of radiotherapy planning, the 
proportion of cases with a clinically significant difference of more than 2 cm between 
PET and EUS was also calculated.  Univariable and multivariable analysis assessed 
association with overall survival (OS).  A p-value of <0.05 was considered 
statistically significant. 
 
Results 
Consecutive patients (n=160, median age 66.0 years (range 24-83), males=124, 
adenocarcinomas=115) staged with PET/CT and EUS between 2011 and 2014 were 
included.  PET tended to under-measure compared to EUS.  The median PET and 
EUS LoD was 6.4 and 8.0 cm, respectively.  PET and EUS LoD was significantly 
different (Z= -7.021, p<0.001).  EUS LoD was more than 2 cm longer than PET LoD 
in 61 cases (38.1%), respectively.  In 8 cases (5.0%), PET LoD was more than 2 cm 
longer than EUS LoD.  Both variables had prognostic significance in univariable 
analysis, but were not independent predictors of OS. 
 
Conclusion 
There are significant differences in PET and EUS measurement of LoD.  This could 
impact on clinical decision-making and radiotherapy treatment planning.  Clinically 
significant differences between EUS and PET LoD could lead to a risk of 
geographical miss in up to 38.1% of cases if the PET/CT measurement alone had 
been used for radiotherapy planning.  These results highlight the continued benefit of 
EUS in the OC staging and treatment pathway. 
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Introduction 
 
Oesophageal cancer (OC) staging uses a multi-modality approach including 
computed tomography (CT), endoscopic ultrasound (EUS) and positron emission 
tomography (PET). [1]  The additional prognostic value of functional imaging means 
PET/CT is now routinely used in cancer staging pathways for patients considered 
suitable for radical therapy. [2]  The two most common histological cell types are 
adenocarcinoma and squamous cell carcinoma (SCC), both of which have a high 
affinity for 18F-fluorodeoxyglucose (18F-FDG), making PET particularly useful in OC. 
 
Primary tumour length is commonly reported following upper gastrointestinal (GI) 
endoscopy, CT, EUS and PET/CT staging investigations. [3]  Of more critical 
importance is the estimated total length of disease (LoD), defined as the cranio-
caudal length of primary tumour plus involved regional lymph nodes.  Assessment of 
treatment options, including suitability for definitive chemo-radiotherapy (dCRT), 
relies on assessment of LoD at staging.  A discrepancy in LoD between imaging 
modalities could affect clinical decision-making and subsequent treatment planning.  
Inappropriate radical treatment may be initiated in unsuitable patients, or potentially 
beneficial therapy could be withheld from those that may respond. 
 
There is now significant interest in the use of PET imaging to assist radiotherapy 
planning, particularly in OC. [4]  Localisation of the gross tumour volume (GTV) in 
radiotherapy planning relies on accurate localisation of the LoD.  Moreover, there 
has been a decline in EUS use nationally, making delineation of the GTV more 
reliant on PET and CT alone. [5] 
 Therefore, this study tested the hypothesis that significant differences exist between 
PET and EUS LoD.  These differences could impact on clinical decision-making and 
treatment planning, especially in cases where EUS is not performed.  The primary 
aim of this study was to investigate differences in PET and EUS LoD in patients with 
OC.  The secondary aim was to assess the prognostic significance of these 
measurements. 
 
 
Materials and Methods 
 
Patient Cohort 
 
Patients staged between January 1st 2011 and December 31st 2014 with biopsy 
proven oesophageal or gastro-oesophageal junction (GOJ) tumours were considered 
for this study.  All EUS examinations were performed by the same operator.  In total, 
222 patients were considered for inclusion.  Exclusion criteria were a non FDG-avid 
primary tumour (n=30), a tumour too stenotic to be passed with the endoscope 
(n=13), LoD not recorded in the EUS report (n=18) and patients lost to follow-up 
(n=1).  Following exclusions, 160 patients were included in the study.  The 
institutional review board gave approval for the study (reference 13//DMD5769).  
Radiological staging was classified according to the Union for International Cancer 
Control (UICC) Tumour Node Metastasis (TNM) 7th edition. [6]   
 
EUS Technique 
 
All EUS examinations were performed by the same highly experienced operator with 
a published track-record, to ensure consistency in LoD measurement. [7]   An initial 
endoscopic examination was performed using a 9 mm diameter Olympus Paediatric 
gastroscope (Olympus, Southend, UK) to assess the degree of oesophageal luminal 
stenosis.  Patients with an estimated oesophageal luminal diameter of less than 15 
mm underwent examination using the smaller-diameter MH-908 oesophagoprobe, 
and if no luminal stenosis, the standard UM-2000 echoendoscope was used 
(Olympus, Southend, UK).  The primary oesophageal tumour was assessed, 
together with an evaluation of the para-oesophageal anatomical structures as 
described previously. [7]  EUS LoD was calculated as the length of endoscope 
insertion relative to the incisors between proximal and distal extent of tumour and 
lymph node metastases if present, recorded in centimetres (cm). [8]  The EUS 
criteria for malignant lymphadenopathy specified a hypo-echoic pattern, spherical 
contour, distinct border, and short axis diameter of 6 mm or more. 
 
PET/CT Protocol 
 
Patients were fasted for at least 6 hours prior to tracer administration.  Serum 
glucose levels were routinely checked and confirmed to be less than 7.0 mmol/L. 
Patients received a dose of 4 MBq of 18F-FDG per kilogram of body weight.  Activity 
uptake time was 90 minutes.  PET/CT imaging was performed with a GE 690 
PET/CT scanner (GE Healthcare, Buckinghamshire, UK).  PET images were 
acquired at 3 minutes per field of view.  The length of the axial field of view was 15.7 
cm.  Images were reconstructed with the ordered subset expectation maximisation 
algorithm, with 24 subsets and 2 iterations.  Matrix size was 256 x 256 pixels, using 
the VUE Point ™ time of flight algorithm.  CT images were acquired in a helical 
acquisition with a pitch of 0.98 and a tube rotation speed of 0.5 seconds.  Tube 
output was 120 kVp with output modulation between 20 and 200 mA.  Matrix size for 
the CT acquisition was 512 x 512 pixels with a 50 cm field of view.  No oral or 
intravenous contrast was administered. 
 
PET Length of Disease Measurement 
 
A single observer (blinded) with 4 years’ experience of PET/CT interpretation 
retrospectively measured and recorded PET LoD (cm) whilst blinded to the originally 
reported PET and EUS LoD.  Measurements were performed on a GE Advantage 
Windows 4.5 reporting workstation (GE Healthcare, Pollards Wood, 
Buckinghamshire, UK) using the maximum intensity projection (MIP) images in the 
rotational plane. (Fig. 1) This allowed visualisation of the greatest perceived LoD.  
Identical viewing settings were used for each case to ensure consistent 
methodology; the field of view (FOV) was 88.1 cm and the SUV of the MIP display 
was maintained at 12 g/ml for each case. 
 
Definition of Regional Nodal disease 
 
Regional lymph nodes were defined as any para-oesophageal lymph node from the 
cervical oesophagus superiorly to the coeliac trunk inferiorly, according to the TNM 
7th edition. [6]  Nodes were classed as involved on PET/CT if the node was identified 
on the CT component and showed FDG uptake appreciably higher than background 
values.  No specific SUVmax was used for the inclusion of regional nodes.  Lymph 
nodes not meeting these criteria were considered benign.  Non-regional lymph 
nodes were considered metastatic (M1). 
 
Treatment Planning and Selection 
 
An appropriate individual management plan was selected based on radiological 
stage, patient choice and relevant comorbidity, according to algorithms used by the 
Regional Upper GI cancer network. [9, 10]  In this study, radiotherapy planning was 
performed using direct comparison of imaging modalities, considering the maximum 
LoD recorded.  Occasionally, non-deformable fusion of the PET and planning CT 
was performed, provided the diagnostic PET/CT had been acquired in the 
radiotherapy planning position to allow accurate fusion. 
 
Survival Data 
 
Overall survival (OS), defined in months survived from the data of diagnosis, was 
used when assessing the prognostic significance of PET and EUS LoD.  Survival 
data was obtained from the Cancer Network Information Service blinded (blinded, 
blinded, Wales).  All patients were followed up 3-monthly in the first year and 6-
monthly thereafter for 5 years, or until death. 
 
Statistical Analysis 
 
Continuous data were expressed as median (range) and categorical data as 
frequency (percent).  A Bland-Altman analysis was used to assess the level of 
agreement between PET and EUS LoD. [11]  The mean difference (PET minus EUS) 
and 95% limits of agreement (LA) were calculated.  A difference of more than 2 cm 
between PET and EUS is considered clinically significant for radiotherapy planning, 
therefore the proportion of cases with a clinically significant difference was also 
calculated. [12]  A non-parametric Wilcoxon signed rank test was used to assess 
differences between PET and EUS LoD.  Univariable survival analysis was 
performed with the log-rank test according to the life-table method of Kaplan-Meier. 
[13]  Multi-variable analysis was performed by entering age (years), stage group (I, 
II, III or IV), treatment (curative or palliative) and individual recorded measurement 
(cm) into a Cox Regression model. [14]  All curative treatments were combined into 
one group in the model rather than entering specific therapies, given the relatively 
small numbers of patients in some treatment groups.  Model power was based on 
the event per variable (EPV) ratio, recommended as a minimum of 10. [15]  A p-
value of <0.05 was considered statistically significant.  Statistical analysis was 
performed using SPSS version 23 (IBM, Chicago, USA). 
Results 
 
Patient characteristics are detailed in Table 1.  The median age of the cohort was 
66.0 years (range 24-83).  The median OS of the cohort was 20.0 months (95% 
confidence interval (CI) 16.2-23.8) and median follow-up was 40.0 months (35.1-
44.9). 
 
The median PET LoD was 6.4 cm (standard deviation (SD) 4.5, interquartile range 
(IQR) 4.5-9.4, range 1.0-25.8), respectively.  The median EUS LoD was 8.0 cm (SD 
5.7, IQR 6.0-12.0, range 1.0-27.0), respectively.  PET tended to yield smaller TL and 
LoD measurements compared to EUS. (Figure 2) 
 
A Wilcoxon signed rank test demonstrated a significant difference between PET and 
EUS LoD (Z= -7.021, p<0.001).  EUS LoD was more than 2 cm longer than PET LoD 
in 61 cases (38.1%).  In 8 cases (5.0%), PET LoD was more than 2 cm longer than 
EUS LoD. 
 
Bland-Altman analysis demonstrated substantial variation in measured PET and 
EUS LoD. (Fig. 3)  The mean difference in LoD (PET minus EUS) was -2.2 cm (SD 
3.8, 95% LA -9.6 to 5.2).  The Bland Altman analysis indicates that the 95% LA 
between PET and EUS LoD represent a level of disagreement that is potentially 
clinically significant, suggesting that PET and EUS LoD should not be used inter-
changeably. (Fig. 4) 
 
In univariable analysis, PET LoD (Hazard Ratio (HR) 1.076, 95% CI 1.037-1.115, 
p<0.001) and EUS LoD (HR 1.059, 95% CI 1.028-1.091, p<0.001) were significantly 
associated with OS. There were significant differences in OS between upper and 
lower quartiles of PET LoD (13.0 months if >9.4 cm and 29.0 months if <4.5 cm, 
p<0.001) and EUS LoD (13.0 months if >12.0 cm and 29.0 months if <6.0 cm, 
p=0.002).  However, in multivariable analysis, these variables were not 
independently associated with OS. (Table 2)  The EPV ratio was 22.2. 
 
 
Discussion 
 
This study has demonstrated significant differences between PET and EUS LoD in 
patients with OC.  Both PET and EUS LoD were significantly associated with OS on 
univariable analysis, but were not independent predictors.  These results are 
important for treatment option assessment, which can be complex in OC.   
 
Selection of patients for surgical management, neo-adjuvant treatments or dCRT 
partly relies on accurate assessment of disease extent, often gained from PET/CT 
and EUS.  The LoD is an important measurement that can influence these decisions.  
These results suggest that PET tends to under-measure LoD compared to EUS.   
 
An accepted maximum LoD for consideration of radiotherapy is 10 cm, as described 
in the SCOPE trial series protocols (17).  There is often more concern about length 
of irradiated volume in the neo-adjuvant setting, leading to a more conservative 
approach in this scenario.  Inaccuracies in LoD estimation could also affect patient 
selection for neo-adjuvant chemoradiotherapy. [16] 
 
In terms of radiotherapy planning, a difference of more than 2 cm between PET and 
EUS is considered clinically significant. [12]  Most modern oesophageal radiotherapy 
planning protocols allow a margin of 2 cm from GTV to clinical target volume (CTV) 
to allow for microscopic spread along the oesophagus.  Differences in LoD of more 
than 2 cm could lead to a significant risk of a geographical miss if the PET 
measurement is used alone.  In this study, up to 38.1% of cases were at risk of a 
geographical miss. 
 Delineation of target volumes for radiotherapy planning is increasingly guided by 
metabolic activity of the primary tumour and regional nodes on PET/CT. [17]  In 
addition to clinical information, PET images are most commonly viewed alongside 
the planning CT.  The oesophageal GTV can be difficult to define on CT alone 
because of submucosal spread, the propensity for skip lesions and poor 
differentiation of tumour from normal oesophagus.  Accurate definition of GTV has 
become even more important given the growing trend for reduced margins combined 
with increased conformity of treatment volumes and use of advanced techniques 
such as Volumetric Modulated Arc Therapy (VMAT).  Some centres use fusion 
techniques, but inaccuracies can be introduced if patient positioning differs between 
diagnostic and planning examinations.  
 
Centres that utilise EUS for radiotherapy planning have reported satisfactory 
recurrence rates with few edge-of-field relapses. [18]  However, EUS is occasionally 
unavailable at the time of radiotherapy planning, often due to non-traversable 
tumour, patient choice or increasing service pressures.  Limited information can still 
be acquired from a non-traversable tumour, such as the proximal extent of tumour 
and assessment of visible lymph nodes, but the maximum LoD may not be fully 
appreciated in these cases.   
 
If PET alone is relied upon to guide delineation of GTV, all available diagnostic 
information, including the upper GI endoscopy report, diagnostic CT and PET/CT 
images, should be used together to plan radiotherapy.  The temptation to outline 
FDG-avid regions of disease alone should be resisted because it is vital to include 
disease identified on all available imaging modalities.  Usually, the most recent 
imaging is the radiotherapy planning CT and areas of adjacent, non-avid 
oesophageal wall thickening should be included in the GTV. This approach is also 
recommended in the recent SCOPE2 trial radiotherapy planning protocol. [19]   
 
EUS assesses local disease more accurately than PET due to its superior contrast 
and spatial resolution.  Submucosal infiltration is also better assessed with EUS. [20]   
Physiological FDG-uptake in the oesophagus or stomach is often located adjacent to 
the tumour, creating an ‘avidity gradient’ which can cause error in measurement.  
Another limitation of PET is the suboptimal differentiation of adjacent peri-tumoural 
lymph node metastases from the primary tumour. [21]  However, PET/CT can add 
useful information in patients with non-traversable tumours, or in cases where there 
is involvement of the GOJ.  Identification of nodal disease distant to the primary 
tumour can also be assessed.  Overall, these results support the combined use of 
PET and EUS in radiation treatment planning of OC. 
 
It has been suggested that EUS use should be more focused in OC.  EUS is an 
invasive procedure with risk of serious complications and is operator dependent.  In 
many centres, access to EUS is limited, which can impact on patient pathways and 
time to treatment.  This is supported by evidence that EUS use is declining.  
According to the National Oesophago-Gastric Cancer Audit (NOGCA) data, 47.5% of 
patients with OC had a staging EUS completed in 2016, compared to 62% reported 
in 2013. [5]  A large single-centre study showed minimal benefit of EUS versus the 
potential risk of complications in the majority of patients staged T2-T4a on CT. [22]  
The authors suggested that EUS use should be limited to early stage OC and the 
assessment of resectability in more advanced cases.  The additional utility of EUS 
for accurate radiotherapy planning was not discussed in this paper and should be an 
additional consideration given the increasing use of neo-adjuvant chemoradiotherapy 
in recent years. 
 
As for other studies investigating imaging measurements, the true pathological 
length is unknown, making accurate comparison of different modalities difficult.  
Cancer resections specimens can shrink up to 50% in size which is an important 
consideration when comparing measurements. [23]  Only measurements from single 
observers for both PET and EUS were analysed in this study, which maintains 
consistent methodology, but does not allow assessment of inter-observer variability.  
Future research should focus on the impact of inter-observer variability on treatment 
decision-making in patients with OC.  Identical settings were used when measuring 
LoD on the PET MIP images.  Some tumours with high intensity variation may not 
have displayed optimally, which potentially introduced error in measurement.  
However, this methodology was adopted to ensure consistency between patients.  In 
addition, the patient population was relatively heterogeneous, which reflects the 
observational nature of the study.  As a result, the patients included in this study 
received different treatments.  Treatment was included in the multi-variable analysis 
as curative and palliative groups only.  Curative therapies were combined as the 
numbers in some treatment groups were relatively small.   
 
In conclusion, this retrospective study has demonstrated significant differences in 
measured PET and EUS LoD from OC staging investigations.  These measurements 
showed prognostic significance on univariable analysis but were not independent 
predictors of survival.  Differences in these measurements could potentially impact 
clinical-decision making and radiotherapy treatment planning.  In our view, these 
results highlight the continued benefit of EUS in the OC staging and treatment 
pathway, particularly adding information in patients requiring radiotherapy. 
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Figure Legends 
 
 
Figure 1. PET maximum intensity projection (MIP) images demonstrating 
measurement of LoD in a 67-year-old gentleman with a mid-oesophageal SCC and 
large FDG-avid regional lymph node metastases. 
 
 Figure 2. Boxplot representation of measured PET and EUS LoD. 
 
 Figure 3. Bland-Altman plot demonstrating limited agreement in measured PET and 
EUS LoD.  The mean difference [PET minus EUS (solid line)] and 95% LA (dashed 
lines) are displayed. 
 
 Figure 4. Selected fused sagittal PET/CT radiotherapy planning image 
demonstrating a FDG-avid mid-oesophageal SCC staged T3 N1 with EUS.  The 
horizontal red lines delineate the GTV incorporating the EUS LoD measurement, 
with each line representing a 5 mm interval.  The PET LoD measured 6.5 cm, 
whereas the EUS LoD was recorded as 10 cm, indicating non-FDG avid tumour at 
proximal and distal margins. 
 
 
 
 
 
 
Table 1. Baseline Characteristics of Patient Cohort 
Patient Characteristic Frequency (%) 
Gender 
Male 
Female 
 
124 (77.5) 
36 (22.5) 
Histology 
Adenocarcinoma 
Squamous Cell Carcinoma 
High-grade Dysplasia 
Neuro-endocrine 
Undifferentiated 
 
115 (71.9) 
41 (25.6) 
2 (1.3) 
1 (0.6) 
1 (0.6) 
Tumour Location 
Oesophagus 
Gastro-oesophageal junction 
 
96 (60.0) 
64 (40.0) 
EUS T-stage 
T1 
T2 
T3 
T4a 
T4b 
 
5 (3.1) 
14 (8.8) 
97 (60.6) 
33 (20.6) 
11 (6.9) 
EUS N-stage 
N0 
N1 
N2 
N3 
 
54 (33.8) 
49 (30.6) 
35 (21.8) 
22 (13.8) 
PET/CT N-stage 
N0 
N1 
N2 
N3 
 
81 (50.6) 
51 (31.8) 
22 (13.8) 
6 (3.8) 
PET/CT M-stage 
M0 
M1 
MX 
 
144 (90.0) 
14 (8.8) 
2 (1.2) 
Treatment 
Neo-adjuvant chemotherapy 
Definitive chemoradiotherapy 
Surgery alone 
Neo-adjuvant chemoradiotherapy 
Endoscopic mucosal resection 
Palliative 
 
37 (23.1) 
35 (21.9) 
17 (10.6) 
14 (8.8) 
1 (0.6) 
56 (35.0) 
 
Table 2. Results of the Multivariable Cox Regression Model 
   95% Confidence Interval 
Variable p-value Hazard Ratio Lower Upper 
Age 0.026 1.024 1.003 1.045 
Stage Group 0.002 1.728 1.227 2.433 
Treatment <0.001 0.414 0.265 0.648 
PET LoD 0.787 0.992 0.933 1.054 
EUS LoD 0.996 1.000 0.950 1.053 
 
 
